<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35357653</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1534-6277</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Current treatment options in oncology</Title>
          <ISOAbbreviation>Curr Treat Options Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia.</ArticleTitle>
        <Pagination>
          <StartPage>775</StartPage>
          <EndPage>795</EndPage>
          <MedlinePgn>775-795</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11864-022-00974-0</ELocationID>
        <Abstract>
          <AbstractText>The better understanding of the biology of chronic lymphocytic leukemia (CLL) gained over the past decade has led to the development and introduction of several targeted drugs, with an demonstrable improvement in the prognosis for this currently incurable condition. Currently, Bruton's tyrosine kinase (BTK) inhibitors, phosphoinositide 3-kinase (PI3K) inhibitors, venetoclax, and CD20 monoclonal antibodies are the key elements in the treatment of both previously untreated and relapsed/refractory CLL patients. Ibrutinib was the first BTK inhibitor approved for clinical use, and showed excellent efficacy and an acceptable safety profile. Following this, the better-tolerated second-generation irreversible BTK inhibitors acalabrutinib and zanubrutinib have been introduced for the treatment of lymphoid malignancies, and acalabrutinib was approved for CLL. When used as single drugs, BTK inhibitors are given continuously until unacceptable toxicity or disease progression; however, when combined with venetoclax and/or CD20 antibodies, they induce deeper response and can be given for a limited time. Recently, promising new reversible BTK inhibitors pirtobrutinib and nemtabrutinib were discovered, and these seem to be more active and better tolerated than their irreversible predecessors. However, they are in an early phase of development and are not currently approved for CLL. The phosphatidylinositol 3-kinase (PI3K) inhibitors idelalisib and duvelisib are highly effective in patients with relapsed CLL, including high-risk disease. The major limitations for their use are adverse events, mostly of autoimmune origin (hepatitis, enteritis/colitis, and pneumonitis). Otherwise, cellular therapies like allogeneic hematopoietic stem cell transplantation and chimeric antigen receptor (CAR) T cells and bispecific monoclonal antibodies offer promise for patients who have failed BTK inhibitors and venetoclax treatment. In the coming years, it is likely that novel targeted therapies will replace immunochemotherapy regimens in most patients.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Iskierka-Jażdżewska</LastName>
            <ForeName>Elżbieta</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0003-2772-8870</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of General Hematology, Copernicus Memorial Hospital, Lodz, Poland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Medical University of Lodz, Lodz, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Obracaj</LastName>
            <ForeName>Agnieszka</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Hematology, Copernicus Memorial Hospital, Lodz, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Urbaniak</LastName>
            <ForeName>Marta</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Hematology, Copernicus Memorial Hospital, Lodz, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Robak</LastName>
            <ForeName>Tadeusz</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-3411-6357</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of General Hematology, Copernicus Memorial Hospital, Lodz, Poland. tadeusz.robak@umed.lodz.pl.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Medical University of Lodz, Lodz, Poland. tadeusz.robak@umed.lodz.pl.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Copernicus Memorial Hospital in Lodz, Ciołkowskiego 2, 93-510, Łódź, Poland. tadeusz.robak@umed.lodz.pl.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>31</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Curr Treat Options Oncol</MedlineTA>
        <NlmUniqueID>100900946</NlmUniqueID>
        <ISSNLinking>1534-6277</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="Y">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015451" MajorTopicYN="Y">Leukemia, Lymphocytic, Chronic, B-Cell</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016393" MajorTopicYN="Y">Lymphoma, B-Cell</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Acalabrutinib</Keyword>
        <Keyword MajorTopicYN="N">BTK inhibitors</Keyword>
        <Keyword MajorTopicYN="N">CLL</Keyword>
        <Keyword MajorTopicYN="N">Ibrutinib</Keyword>
        <Keyword MajorTopicYN="N">Idelalisib</Keyword>
        <Keyword MajorTopicYN="N">MRD</Keyword>
        <Keyword MajorTopicYN="N">Nemtabrutinib</Keyword>
        <Keyword MajorTopicYN="N">Pirtobrutinib</Keyword>
        <Keyword MajorTopicYN="N">Venetoclax</Keyword>
        <Keyword MajorTopicYN="N">Zanabrutinib</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>31</Day>
          <Hour>12</Hour>
          <Minute>6</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35357653</ArticleId>
        <ArticleId IdType="doi">10.1007/s11864-022-00974-0</ArticleId>
        <ArticleId IdType="pii">10.1007/s11864-022-00974-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References and Recommended Reading</Title>
        <ReferenceList>
          <Title>Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance</Title>
          <Reference>
            <Citation>Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021;96(12):1679–705. https://doi.org/10.1002/ajh.26367 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1002/ajh.26367</ArticleId>
              <ArticleId IdType="pubmed">34625994</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:23–33. https://doi.org/10.1016/j.annonc.2020.09.019 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1016/j.annonc.2020.09.019</ArticleId>
              <ArticleId IdType="pubmed">33091559</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.3322/caac.21708</ArticleId>
              <ArticleId IdType="pubmed">35020204</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R, et al. French Cooperative Group on Chronic Lymphocytic Leukemia. Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med. 1998;338(21):1506–14. https://doi.org/10.1056/NEJM199805213382104 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1056/NEJM199805213382104</ArticleId>
              <ArticleId IdType="pubmed">9593789</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Herling CD, Cymbalista F, Groß-Ophoff-Müller C, Bahlo J, Robrecht S, Langerbeins P, et al. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. Leukemia. 2020;34(8):2038–50. https://doi.org/10.1038/s41375-020-0747-7 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1038/s41375-020-0747-7</ArticleId>
              <ArticleId IdType="pubmed">32071431</ArticleId>
              <ArticleId IdType="pmc">7387319</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>•• Langerbeins P, Zhang C, Robrecht S, Cramer P, Fürstenau M, Al-Sawaf O, von Tresckow J, et al. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. Blood. 2022;139(2):177–87. https://doi.org/10.1182/blood.2021010845 .</Citation>
          </Reference>
          <Reference>
            <Citation>Robak P, Robak T. Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2017;26(11):1249–65. https://doi.org/10.1080/13543784.2017.1384814 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1080/13543784.2017.1384814</ArticleId>
              <ArticleId IdType="pubmed">28942659</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum K, et al. Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib/II PCYC-1102 study. Clin Cancer Res. 2020;26(15):3918–27. https://doi.org/10.1158/1078-0432.CCR-19-2856 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1158/1078-0432.CCR-19-2856</ArticleId>
              <ArticleId IdType="pubmed">32209572</ArticleId>
              <ArticleId IdType="pmc">8175012</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019;133(19):2031–42. https://doi.org/10.1182/blood-2018-08-870238 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1182/blood-2018-08-870238</ArticleId>
              <ArticleId IdType="pubmed">30842083</ArticleId>
              <ArticleId IdType="pmc">6509542</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353–63. https://doi.org/10.1002/ajh.25638 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1002/ajh.25638</ArticleId>
              <ArticleId IdType="pubmed">31512258</ArticleId>
              <ArticleId IdType="pmc">6899718</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>•• Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34(3):787–98. https://doi.org/10.1038/s41375-019-0602-x This reference is of outstanding importance because presents important results with long-term follow-up in patients with TN-CLL/SLL treated with ibrutinib.</Citation>
          </Reference>
          <Reference>
            <Citation>Hillmen P, Fraser G, Jones J, Rule S, Brien S, Dilhuydy MS, et al. Comparing single-agent ibrutinib, bendamustine plus rituximab (BR) and ibrutinib plus BR in patients with previously-treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an in-direct comparison of the RESONATE and HELIOS trials. Blood. 2015;129:2944. https://doi.org/10.1182/blood.V126.23.2944.2944 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1182/blood.V126.23.2944.2944</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Fraser G, Cramer P, Demirkan F, Silva RS, Grosicki S, Pristupa A, et al. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia. 2019;33(4):969–80. https://doi.org/10.1038/s41375-018-0276-9 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1038/s41375-018-0276-9</ArticleId>
              <ArticleId IdType="pubmed">30315239</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43–56. https://doi.org/10.1016/S1470-2045(18)30788-5 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1016/S1470-2045(18)30788-5</ArticleId>
              <ArticleId IdType="pubmed">30522969</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>•• Shanafelt TD, Wang XV, Kay NE, Hanson CA, O'Brien S, Barrientos J, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432–43. https://doi.org/10.1056/NEJMoa1817073 This reference is of outstanding importance because reveals superior safety and efficacy of ibrutinib-rituximab approach compared with chemoimmunotherapy in CLL patients with unmutated IGHV.</Citation>
          </Reference>
          <Reference>
            <Citation>Sharman, J.P.; Egyed,M.; Jurczak,W.; Skarbnik, A.; Pagel, J.M.; Kamdar, M.K.;Munir, T.; Corbett, G.; Fogliatto, L.M.; Herishanu, Y.; et al. Acalabrutinib _ obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Elevate-TN four-year follow up. J Clin Oncol 2021, 39, 7509.</Citation>
          </Reference>
          <Reference>
            <Citation>•• Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, Kaplan, et al. ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38(25):2849–61. https://doi.org/10.1200/JCO.19.03355 This reference is of importance because reveals superior safety and similar efficacy of acalabrutinib compared with ibrutinib in RR-CLL/SLL.</Citation>
          </Reference>
          <Reference>
            <Citation>Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocyticleukemia. N Engl J Med. 2016;374(4):311–22. https://doi.org/10.1056/NEJMoa1513257 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1056/NEJMoa1513257</ArticleId>
              <ArticleId IdType="pubmed">26639348</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–20. https://doi.org/10.1056/NEJMoa1713976 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1056/NEJMoa1713976</ArticleId>
              <ArticleId IdType="pubmed">29562156</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Kater AP, Wu JQ, Kipps T, Eichhorst B, Hillmen P, D'Rozario J, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study. J Clin Oncol. 2020;38(34):4042–54. https://doi.org/10.1200/JCO.20.00948 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1200/JCO.20.00948</ArticleId>
              <ArticleId IdType="pubmed">32986498</ArticleId>
              <ArticleId IdType="pmc">7768340</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>•• Fischer K, Al-Sawaf O, Bahlo J, Fink A-M, Tandon M, Dixon M, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–36. https://doi.org/10.1056/NEJMoa1815281 This reference is of importance because reveals good safety and efficacy of therapy with venetoclax and obinutuzumab in unfit patients with CLL/SLL.</Citation>
          </Reference>
          <Reference>
            <Citation>Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007. https://doi.org/10.1056/nejmoa1315226 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1056/nejmoa1315226</ArticleId>
              <ArticleId IdType="pubmed">24450857</ArticleId>
              <ArticleId IdType="pmc">4161365</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018;132:2446–55. https://doi.org/10.1182/blood-2018-05-850461 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1182/blood-2018-05-850461</ArticleId>
              <ArticleId IdType="pubmed">30287523</ArticleId>
              <ArticleId IdType="pmc">6284216</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–37. https://doi.org/10.1056/NEJMoa1509388 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1056/NEJMoa1509388</ArticleId>
              <ArticleId IdType="pubmed">26639149</ArticleId>
              <ArticleId IdType="pmc">4722809</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123:3390–7. https://doi.org/10.1182/blood-2013-11-535047 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1182/blood-2013-11-535047</ArticleId>
              <ArticleId IdType="pubmed">24615777</ArticleId>
              <ArticleId IdType="pmc">4123414</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323–32. https://doi.org/10.1056/NEJMoa1509981 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1056/NEJMoa1509981</ArticleId>
              <ArticleId IdType="pubmed">26641137</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Tambaro FP, De Novellis D, Wierda WG. The role of BTK inhibition in the treatment of chronic lymphocytic leukemia: a clinical view. J Exp Pharmacol. 2021;13:923–35. https://doi.org/10.2147/JEP.S265284 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.2147/JEP.S265284</ArticleId>
              <ArticleId IdType="pubmed">34744463</ArticleId>
              <ArticleId IdType="pmc">8565990</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, Pals ST, Spaargaren M. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119(11):2590–4. https://doi.org/10.1182/blood-2011-11-390989 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1182/blood-2011-11-390989</ArticleId>
              <ArticleId IdType="pubmed">22279054</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Robak T, Robak P. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies. Int Rev Immunol. 2013;32(4):358–76. https://doi.org/10.3109/08830185.2013.786711 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.3109/08830185.2013.786711</ArticleId>
              <ArticleId IdType="pubmed">23617253</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–28. https://doi.org/10.1056/NEJMoa1812836 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1056/NEJMoa1812836</ArticleId>
              <ArticleId IdType="pubmed">30501481</ArticleId>
              <ArticleId IdType="pmc">6325637</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Sharman JP, Brander DM, Mato AR, Ghosh N, Schuster SJ, Kambhampati S, et al. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial. Lancet Haematol. 2021;8:e254–e66. https://doi.org/10.1016/S2352-3026(20)30433-6 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1016/S2352-3026(20)30433-6</ArticleId>
              <ArticleId IdType="pubmed">33631112</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>•• Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39(31):3441–52. https://doi.org/10.1200/JCO.21.01210 This reference is of importance because reveals superior safety and similar efficacy of acalabrutinib compared with ibrutinib in RR-CLL/SLL.</Citation>
          </Reference>
          <Reference>
            <Citation>•• Hillmen P, Brown JR, Eichhorst BF, Lamanna N, O'Brien SM, Qiu L, et al. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Future Oncol. 2020;16(10):517–23. https://doi.org/10.2217/fon-2019-0844 This reference is of importance because reveals superior safety and efficacy of zanubrutinib compared with ibrutinib in RR-CLL/SLL.</Citation>
          </Reference>
          <Reference>
            <Citation>Hillmen P, Eichhorst B, Brown JR, Lamanna N, O'Brien S, Tam CS, et al. First interim analysis of alpine study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. EHA Library. 06/11/21; 330170; LB1900.</Citation>
          </Reference>
          <Reference>
            <Citation>Tam C, Giannopoulos K, Jurczak W, Šimkovič M, Shadman M, Österborg A, et al. SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Blood 2021;138: (Suppl. 1), Abstract 396). https://doi.org/10.1182/blood-2021-148457</Citation>
          </Reference>
          <Reference>
            <Citation>Allan JN, Shanafelt T, Wiestner A, Moreno C, O'Brien SM, Li J, et al. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials. Br J Haematol. 2022;196(4):947–53. https://doi.org/10.1111/bjh.17984 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1111/bjh.17984</ArticleId>
              <ArticleId IdType="pubmed">34865212</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>•• Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019;380(22):2095–103. https://doi.org/10.1056/NEJMoa1900574 This reference is of importance because presented promissing results of combinig therapy with BTK- and BCL2 inhibitors as a first-line therapy.</Citation>
          </Reference>
          <Reference>
            <Citation>Kater A, Owen C, Moreno C, Follows G, Munir T., Levin MD, et al. Fixed-dyration ibrutinib and venetoclax (I+V) versus chlorambucil plus Obinutuzumab (CLB+O) for first line chronic lymphocytoc leukemia: primary analysis of the phase 3 GLOW study. EHA 2021. Abstract: LB1902.</Citation>
          </Reference>
          <Reference>
            <Citation>Fürstenau M, Eichhorst B. Novel agents in chronic lymphocytic leukemia: new combination therapies and strategies to overcome resistance. Cancers (Basel). 2021;13(6):1336. https://doi.org/10.3390/cancers13061336 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.3390/cancers13061336</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, et al. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood. 2019;134(2):111–22. https://doi.org/10.1182/blood.2018882555 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1182/blood.2018882555</ArticleId>
              <ArticleId IdType="pubmed">31023700</ArticleId>
              <ArticleId IdType="pmc">6624969</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>O'Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K, et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018;131(17):1910–9. https://doi.org/10.1182/blood-2017-10-810044 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1182/blood-2017-10-810044</ArticleId>
              <ArticleId IdType="pubmed">29437592</ArticleId>
              <ArticleId IdType="pmc">5921964</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208–15. https://doi.org/10.1182/blood-2015-06-651125 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1182/blood-2015-06-651125</ArticleId>
              <ArticleId IdType="pubmed">26486789</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019;133(10):1011–9. https://doi.org/10.1182/blood-2018-10-879429 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1182/blood-2018-10-879429</ArticleId>
              <ArticleId IdType="pubmed">30530801</ArticleId>
              <ArticleId IdType="pmc">6405333</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Collett L, Howard DR, Munir T, McParland L, Oughton JB, Rawstron AC, et al. Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. Trials. 2017;18(1):387. https://doi.org/10.1186/s13063-017-2138-6 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1186/s13063-017-2138-6</ArticleId>
              <ArticleId IdType="pubmed">28830517</ArticleId>
              <ArticleId IdType="pmc">5568356</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Pitchford A , Bloor A, Broom A, Young M, Kennedy B, Walewska R et al.<sup>.</sup> Ibrutinib plus rituximab is superior to FCR in previously untreated CLL: results of the Phase III NCRI FLAIR Trial. Blood 2021; 138 (Suppl): Abstract 642.</Citation>
          </Reference>
          <Reference>
            <Citation>Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, et al.; Blood Cancer Research Partnership of the Leukemia &amp; Lymphoma Society. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019 A;6(8):e419-e28. https://doi.org/10.1016/S2352-3026(19)30104-8 .</Citation>
          </Reference>
          <Reference>
            <Citation>Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, et al. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021;35(12):3421–9. https://doi.org/10.1038/s41375-021-01280-8 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1038/s41375-021-01280-8</ArticleId>
              <ArticleId IdType="pubmed">34007049</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, et al. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019;6(8):e419–28. https://doi.org/10.1016/S2352-3026(19)30104-8 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1016/S2352-3026(19)30104-8</ArticleId>
              <ArticleId IdType="pubmed">31208944</ArticleId>
              <ArticleId IdType="pmc">7036668</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Herman SEM, Montraveta A, Niemann CU, Mora-Jensen H, Gulrajani M, Krantz F, Mantel R, Smith LL, McClanahan F, Harrington BK, Colomer D, Covey T, Byrd JC, Izumi R, Kaptein A, Ulrich R, Johnson AJ, Lannutti BJ, Wiestner A, Woyach JA. The Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia. Clin Cancer Res. 2017;23(11):2831–41. https://doi.org/10.1158/1078-0432.CCR-16-0463 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1158/1078-0432.CCR-16-0463</ArticleId>
              <ArticleId IdType="pubmed">27903679</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Li N, Sun Z, Liu Y, Guo M, Zhang Y, Zhou D. BGB-3111 is a novel and highly selective Bruton’s tyrosine kinase (BTK) inhibitor [Abstract]. Cancer Res. 2015;75:2597. https://doi.org/10.1158/1538-7445.AM2015-2597 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1158/1538-7445.AM2015-2597</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134(11):851–9. https://doi.org/10.1182/blood.2019001160 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1182/blood.2019001160</ArticleId>
              <ArticleId IdType="pubmed">31340982</ArticleId>
              <ArticleId IdType="pmc">6742923</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Xu W, Yang S, Zhou K, Pan L, Li Z, Zhou J, et al. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. J Hematol Oncol. 2020;13(1):48. https://doi.org/10.1186/s13045-020-00884-4 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1186/s13045-020-00884-4</ArticleId>
              <ArticleId IdType="pubmed">32393328</ArticleId>
              <ArticleId IdType="pmc">7216400</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>•• Tam CS, Robak T, Ghia P, Kahl BS, Walker P, Janowski W, et al. Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion. Haematologica. 2020;106(9):2354–63. https://doi.org/10.3324/haematol.2020.259432 This reference is of importance because presents promising results of zanabrutinib monotherapy in TN-CLL/SLL with deletion17p.</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.3324/haematol.2020.259432</ArticleId>
              <ArticleId IdType="pubmed">33054121</ArticleId>
              <ArticleId IdType="pmc">8409041</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>•• Robak T, Witkowska M, Smolewski P. The role of Bruton’s kinase inhibitors in chronic lymphocytic leukemia: current status and future directions. Cancers (Basel). 2022;14:771. https://doi.org/10.3390/cancers14030771 This reference is of importance because presents current knowledge about BTK inhibitors.</Citation>
          </Reference>
          <Reference>
            <Citation>Gomez EB, Isabel L, Rosendahal MS, Rothenberg SM, Andrews SW, Brandhuber BJ. Loxo-305, a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. Blood. 2019;134(Supplement_1):4644. https://doi.org/10.1182/blood-2019-126114 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1182/blood-2019-126114</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>•• Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397(10277):892–901. https://doi.org/10.1016/S0140-6736(21)00224-5 This reference is of importance because reveals promising results of next-generation BTK inhibitor—pirtobrutinib in RR-CLL/SLL.</Citation>
          </Reference>
          <Reference>
            <Citation>Jurczak W, Shah NN, Lamanna N, Eyre TA, Woyach J, Lech-Maranda E, et al. Pirtobrutinib (loxo-305), a next generation highly selective non-covalent btk inhibitor in previously treated Richter transformation: results from the phase 1/2 bruin study. Hematol Oncol. 2021;39(S2). https://doi.org/10.1002/hon.41_2880 .</Citation>
          </Reference>
          <Reference>
            <Citation>Woyach J, Stephens DM, Flinn IW, Bhat SA, Savage RE, Chai F, et al. Final results of phase 1, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-cell lymphoid malignancies. Blood. 2019;134(Supplement 1):4298. https://doi.org/10.1182/blood-2019-127260 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1182/blood-2019-127260</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, et al. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol. 2019;37:1391–402. https://doi.org/10.1200/JCO.18.01460 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1200/JCO.18.01460</ArticleId>
              <ArticleId IdType="pubmed">30995176</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Jones JA, Robak T, Brown JR, Awan FT, Badoux X, Coutre S, et al. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol. 2017;4(3):e114–e26. https://doi.org/10.1016/S2352-3026(17)30019-4 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1016/S2352-3026(17)30019-4</ArticleId>
              <ArticleId IdType="pubmed">28257752</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017;18:297–311. https://doi.org/10.1016/S1470-2045(16)30671-4 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1016/S1470-2045(16)30671-4</ArticleId>
              <ArticleId IdType="pubmed">28139405</ArticleId>
              <ArticleId IdType="pmc">5589180</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128(2):195–203. https://doi.org/10.1182/blood-2016-03-707133 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1182/blood-2016-03-707133</ArticleId>
              <ArticleId IdType="pubmed">27247136</ArticleId>
              <ArticleId IdType="pmc">4946200</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Tarantelli C, Argnani L, Zinzani PL, Bertoni F. PI3Kδ inhibitors as immunomodulatory agents for the treatment of lymphoma patients. Cancers (Basel). 2021;13:5535. https://doi.org/10.3390/cancers13215535 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.3390/cancers13215535</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Vogler M, Dinsdale D, Dyer MJ, Cohen GM. ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. Br J Haematol. 2013;163(1):139–42. https://doi.org/10.1111/bjh.12457 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1111/bjh.12457</ArticleId>
              <ArticleId IdType="pubmed">23826785</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018;36(19):1973–80. https://doi.org/10.1200/JCO.2017.76.6840 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1200/JCO.2017.76.6840</ArticleId>
              <ArticleId IdType="pubmed">29715056</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Korycka-Wolowiec A, Wolowiec D, Kubiak-Mlonka A, Robak T. Venetoclax in the treatment of chronic lymphocytic leukemia. Expert Opin Drug Metab Toxicol. 2019;15(5):353–66. https://doi.org/10.1080/17425255.2019.1606211.61 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1080/17425255.2019.1606211.61</ArticleId>
              <ArticleId IdType="pubmed">30969139</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Iskierka-Jażdżewska E, Robak T. Investigational treatments for chronic lymphocytic leukemia: a focus on phase 1 and 2 clinical trials. Expert Opin Investig Drugs. 2020;29(7):709–22. https://doi.org/10.1080/13543784.2020.1770225 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1080/13543784.2020.1770225</ArticleId>
              <ArticleId IdType="pubmed">32407139</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(9):1188–200. https://doi.org/10.1016/S1470-2045(20)30443-5 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1016/S1470-2045(20)30443-5</ArticleId>
              <ArticleId IdType="pubmed">32888452</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Munir T, Moreno C, Owen C, Follows GA, Benjamini O, Janssens A, et al. First prospective data on minimal residual disease (MRD) outcomes after fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of CLL in elderly or unfit patients: the Glow Study. Blood 2021; 138 (Suppl): Abstract 70.</Citation>
          </Reference>
          <Reference>
            <Citation>Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, Keating MJ, Balakrishnan K, et al. Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clin Cancer Res. 2015;21:3705–15.11. https://doi.org/10.1158/1078-0432.CCR-14-2809 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1158/1078-0432.CCR-14-2809</ArticleId>
              <ArticleId IdType="pubmed">25829398</ArticleId>
              <ArticleId IdType="pmc">4537801</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Deng J, Isik E, Fernandes SM, Brown JR, Letai A, Davids MS. Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia. 2017;31:2075–84. https://doi.org/10.1038/leu.2017.32 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1038/leu.2017.32</ArticleId>
              <ArticleId IdType="pubmed">28111464</ArticleId>
              <ArticleId IdType="pmc">5555835</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Hillmen P, Brown JR, Byrd JC, Eichhorst B, Lamanna N, O’Brien SM, et al. ALPINE: phase III zanubrutinib (BGB-3111) versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). J Clin Oncol. 2019;37(Suppl. 15):TPS7572. https://doi.org/10.1200/JCO.2019.37.15_suppl.TPS7572 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1200/JCO.2019.37.15_suppl.TPS7572</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019;380(22):2095–103. https://doi.org/10.1056/NEJMoa1900574 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1056/NEJMoa1900574</ArticleId>
              <ArticleId IdType="pubmed">31141631</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Wierda WG, Tam CS, Allan JN, Siddiqi T, Kipps TJ, Opat S, et al. Ibrutinib (Ibr) plus venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 1-year disease-free survival (DFS): results from the MRD cohort of the phase 2 CAPTIVATE Study. Blood. 2020;136:16–7. https://doi.org/10.1182/blood-2020-134446 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1182/blood-2020-134446</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Rogers KA, Huang Y, Ruppert AS, Abruzzo LV, Andersen BL, Awan FT, et al. Phase II study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-naïve and relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38:3626–37. https://doi.org/10.1200/JCO.20.00491 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1200/JCO.20.00491</ArticleId>
              <ArticleId IdType="pubmed">32795224</ArticleId>
              <ArticleId IdType="pmc">7605394</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Huber H, Edenhofer S, von Tresckow J, Robrecht S, Zhang C, Tausch E, et al. Phase 2 study of obinutuzumab (GA-101), ibrutinib and venetoclax (CLL2-GIVe) in patients with untreated high-risk chronic lymphocytic leukemia. Blood. 2021 Dec 15:blood.2021013208. https://doi.org/10.1182/blood.2021013208</Citation>
          </Reference>
          <Reference>
            <Citation>•• Davids MS, Lampson BL, Tyekucheva S, Wang Z, Pazienza S, Montegaard J, et al. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. Lancet Oncol. 2021;22:1391–402. https://doi.org/10.1016/S1470-2045(21)00455-1 This reference is of importance because presents important results of combining therapy with acalabrutinib, venetoclax, and obinutuzumab in TN-CLL.</Citation>
          </Reference>
          <Reference>
            <Citation>Tedeschi A, Ferrant E, Flinn IW, Tam CS, Ghia P, Robak T, et al. Zanubrutinib in combination with venetoclax for patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): early results from Arm D of the SEQUOIA (BGB-3111-304) trial. Blood 2021; 138 (Suppl): Abstract 67.</Citation>
          </Reference>
          <Reference>
            <Citation>Soumerai JD, Mato AR, Dogan A, Seshan VE, Joffe E, Flaherty K, et al. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2021;8(12):e879–e90. https://doi.org/10.1016/S2352-3026(21)00307-0 .</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1016/S2352-3026(21)00307-0</ArticleId>
              <ArticleId IdType="pubmed">34826411</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
